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INTRODUCTION 
               Lymphomas are neoplasms of the immune system. Lymphomas 
are of two types, namely, Hodgkin’s and Non Hodgkin’s lymphoma 
(NHL). Malignant cells affecting the organs such as Gastrointestinal tract, 
brain and skin other than lymph node are referred to as extranodal 
lymphoma. Extranodal lymphomas are mainly non Hodgkin’s type 
commonly involving gastrointestinal tract.
 [1]
Gastrointestinal lymphoma 
constitutes about 10-15% of all non Hodgkin’s lymphoma and about 30-
40% of all extranodal lymphoma. Pediatric lymphoma differs from adult 
lymphoma due to their differences in target cells and exposure to 
environmental agents.  
Between 2007 to 2011, 30 patients presented with intestinal 
lymphoma in Children Hospital whereas in adults stomach is the most 
common site.
 [2] 
Recently, Prognosis for childhood gastrointestinal lymphoma 
improves with realization because all cases are disseminated at diagnosis 
and systemic therapy is needed for long term disease free survival.
 [3] 
The aim of this thesis is to clarify the clinicopathological features 
of paediatric gastrointestinal B cell lymphoma in our institution, to 
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identify the preferred lines of treatment, to correlate with outcome and 
finally to identify the significant prognostic factors. 
Childhood malignancies fall into a smaller number of categories, 
with uniform pathology, immunophenotyping, cytogenetic, clinical 
features, response to therapy and relative frequency. Prognosis of 
lymphoma is based mainly on the histological type and stage of the 
disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS AND 
OJECTIVES
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AIMS AND OBJECTIVES 
The primary aims and objectives of this thesis are  
1. To study the clinicopathological characteristics of paediatric 
lymphomas and to evaluate the conventional morphological 
prognostic parameters among the various histopathological 
subtypes by immunophenotyping. 
2. To study the expression of Immunohistochemical markers in 
lymphomas. 
3. To study the advantages of Immunohistochemistry in 
differentiating Lymphoma from other small round cell tumour by 
Proliferative marker. 
 
 
 
 
 
 
 
 
 
 
 
REVIEW   OF 
LITERATURE
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 REVIEW OF LITERATURE 
Primary tumors of gastrointestinal lymphoma in children are rare 
and represent less than 5% of all pediatric neoplasm
 [4]
. NHL is the most 
common malignancy of the gastrointestinal tract in children 
[5]
. 
          There are several different histological classifications available 
starting from working formulation and Kiel classification, now 
REAL/WHO classification is applied which recognizes the fundamental 
distinction between Hodgkins and non Hodgkins lymphoma. Hodgkins in 
extranodal sites are rare, non Hodgkins lymphoma are classified into B 
cell and T cell type, and each group is further classified into precursor 
cell or mature cell lymphomas. B cell type constitutes more than 80% of 
all lymphomas and have good prognosis as they generally respond to 
chemotherapy. B cell type affecting GIT includes Precursor B cell 
lymphoma, Burkitts lymphoma, Diffuse large Bcell lymphoma (DLBCL), 
Follicular lymphoma (FL) and extranodal marginal zone lymphoma. T 
cell type affecting GIT includes precursor T cell lymphoma, Anaplastic 
large cell lymphoma, Enteropathy associated T cell lymphoma and 
extranodal NK / T cell lymphoma. 
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Small intestine is the most common extranodal GIT involvement in 
paediatric patients, whereas in adults, stomach is the most common site of 
GIT involvement. 
 The latest (2008)  REAL/WHO classification was listed here. 
The REAL/ WHO classification (2008) 
 
B-cell neoplasms  
Precursor B-cell neoplasm  
    B lymphoblastic leukemia/lymphoma 
Mature B-cell neoplasms  
    Chronic lymphocytic leukemia/small lymphocytic lymphoma 
    B-cell prolymphocytic leukemia 
    Lymphoplasmacytic lymphoma 
    Splenic marginal zone lymphoma 
    Hairy cell leukemia 
    Plasma cell neoplasms (plasma cell myeloma/plasmacytoma) 
   
 Extranodal marginal zone lymphoma of mucosa-associated 
lymphoid tissue (MALT-lymphoma) 
    Nodal marginal zone lymphoma 
    Follicular lymphoma 
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    Primary cutaneous follicle center lymphoma 
    Mantle cell lymphoma 
   
 Diffuse large B-cell lymphomas (DLBCL)  
    DLBCL, not otherwise specified 
    T-cell/histiocyte-rich large B-cell lymphoma 
    Primary DLBCL of the central nervous system 
    Primary cutaneous DLBCL, leg-type 
    Epstein–Barr virus + DLBCL of the elderly 
    Primary mediastinal (thymic) large B-cell lymphoma 
    Intravascular large B-cell lymphoma 
    DLBCL associated with chronic inflammation 
    Lymphomatoid granulomatosis 
    ALK+ large B-cell lymphoma 
    Plasmablastic lymphoma 
   
 Large B-cell lymphoma arising in HHV8-associated 
 multicentric Castleman disease 
   
 Primary effusion lymphoma 
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    Burkitt lymphoma 
   
 B-cell lymphoma, unclassifiable, with features intermediate 
 between diffuse large B-cell lymphoma and Burkitt 
 lymphoma 
   
 B-cell lymphoma, unclassifiable, with features intermediate 
 between diffuse large B-cell lymphoma and classical 
 Hodgkin lymphoma 
T-cell and NK-cell neoplasms  
Precursor T-cell neoplasms  
    T lymphoblastic leukemia/lymphoma 
Mature T-cell and NK cell neoplasms  
    T-cell prolymphocytic leukemia 
    T-cell large granular lymphocytic leukemia 
    Aggressive NK cell leukemia 
    Adult T-cell leukemia/lymphoma 
   
 Epstein–Barr virus + T-cell lymphoproliferative diseases of 
 childhood 
    Extranodal NK-/T-cell lymphoma, nasal type 
    Enteropathy-associated T-cell lymphoma 
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    Hepatosplenic T-cell lymphoma 
    Subcutaneous panniculitis-like T-cell lymphoma 
    Mycosis fungoides 
    Sézary syndrome 
   
 Primary cutaneous CD30+ T-cell lymphoproliferative 
 disorders 
   
 Primary cutaneous peripheral T-cell lymphomas, rare 
 subtypes 
    Peripheral T-cell lymphoma, not otherwise specified 
    Angioimmunoblastic T-cell lymphoma 
    Anaplastic large cell lymphoma, ALK+/ALK- 
 
 
BURKITT’S LYMPHOMA: 
 Burkitt’s lymphoma is an aggressive lymphoma that may occur as 
endemic in equatorial Africa or sporadic disease 
[6]
.
 
It is associated with 
EBV infection in almost 20% of cases.
 [7]
 Burkitt’s lymphoma generally 
affects younger populations and is typically located in the cardia or body 
of stomach or terminal Ileum.
 [7, 8] 
Apoptosis and mitosis are common 
within the tumour, which attracts circulating macrophages and thereby 
results in classic starry sky pattern. Burkitt’s  lymphoma generally 
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expresses CD10, CD20,CD79a and Bcl-6 but lacks Bcl-2 and 
rearrangement of the c-myc oncogene is typical of Burkitt type.
 [9]
 
DIFFUSE LARGE B CELL LYMPHOMA (DLBCL):  
Diffuse large B cell lymphoma may occur denovo or arise from 
pre-existing low grade lymphoma, Chronic lymphocytic leukemia, small 
lymphocytic lymphoma, or follicular lymphoma.
[6,8] 
It is a B cell 
lymphoma which constitutes 20% of paediatric NHL. Morphological 
variants are centroblastic and immunoblastic. It occurs in older children 
and adolescents. DLBCL manifests as a tumour mass replacing the 
normal architecture of the tissue and is most commonly located in the 
stomach or ileocaecal region. 
[6]
 
There are several morphological variants of DLBCL that are 
distinguished by histological, cytogenetic, and molecular genetics 
features; patterns of gene expression dictate the prognosis (14, 15). A 
Bcl-2 gene mutation, commonly involved in a (14; 18) (q32; q21) 
translocation, is present in 10% to 40% of DLBCL, and a Bcl-6 gene 
mutation with a (14; 3) (q32; q27) rearrangement may occur in 30% to 
40% of cases. Bcl-2 protein is involved in the prevention of apoptosis, 
and recent evidence suggests that over expression of it is associated with 
decreased overall and disease free survival. 
[10] 
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LYMPHOBLASTIC LYMPHOMA (LL):  
Lymphoblastic lymphoma is seen primarily in children and 
adolescents and constitutes 20% of paediatric NHL,
[11, 12]
 It has a 
distinctive clinical presentation. In approximately half of the cases, there 
is a mediastinal mass in the thymic region (the old term called Sternberg 
sarcoma). The clinical course of the untreated disease is extremely 
aggressive, with rapid multisystem dissemination, leukemic blood picture 
(acute lymphoblastic leukemia),
 [13]
 and death after a few months.
 [14]
 
         Macroscopically, the tumour is soft and Grey white and shows foci 
of haemorrhage and necrosis. Microscopically, there is a diffuse and 
relatively monomorphic pattern of proliferation with starry sky 
appearance in some of the cases. The tumour often extends outside the 
node or thymus and invades the adipose tissue in a diffuse fashion. The 
neoplastic cells have scanty cytoplasm and a nucleus that has a round 
contour with the presence of delicate convolutions resulting from 
invaginations of the nuclear membrane. 
Lymphoblastic lymphoma (LL) also affect other organs such as 
involvement of bone, skin, bone marrow, CNS, abdominal organs rarely 
bowel, and occasionally lymphoid tissue of Waldeyer ring and testes. 80–
85% of lymphoblastic lymphomas show T-cell markers while the 
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remaining 15% to 20% show B-cell markers. The phenotypes of 
Lymphoblastic lymphoma recapitulate those of the various stages of 
intrathymic T-cell differentiation, i.e., those of the precursor  
T lymphoblast, hence designate this tumour as precursor T lymphoblastic 
lymphoma (and as precursor T lymphoblastic leukaemia when extensive 
marrow and peripheral blood involvement are present).
 [15]
 
       T cell Lymphoblastic Lymphoma expresses CD1, CD2, CD7, 
cytoplasmic CD3 and CD43. B cell type of Lymphoblastic Lymphoma 
express CD19, CD20, CD21 and CD24.
[16]
 
ANAPLASTIC LARGE CELL LYMPHOMA (ALCL):  
Anaplastic large cell lymphoma constitutes 10% of paediatric 
NHL. It is predominantly of mature T cell type and is a rare entity which 
is defined by the presence of rearrangement in the ALK gene on 
chromosome 2p23. It occurs in children and young adults involving GIT 
and soft tissue and carry a very good prognosis with a cure rate of 75%. 
Histology shows the tumor cells composed of large anaplastic cells with 
horse shoe shaped nuclei and voluminous cytoplasm called hallmark cell. 
Hence the detection of ALK protein in tumor cells is the reliable indicator 
of gene rearrangement. The tumour cells express marker CD30.
 [17, 18, 19, 20] 
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           Clinically,  anaplastic lymphoma shows two types of presentation, 
namely a systemic form and a primary cutaneous form (without 
extracutaneous involvement).
 [21, 22, 23]
 
           The systemic form of ALCL  involves lymph nodes  and 
extranodal sites, such as the bone marrow, bone, respiratory tract, skin, 
and gastrointestinal tract.
[24,25,26]
 It can occur in children or adults, having 
an  aggressive behaviour.
[27,28,29,30] 
Systemic type also manifest leukemic 
manifestations.
[31] 
           Histology shows the infiltrate has a polymorphic appearance, often 
with a variable admixture of neutrophils, lymphocytes, and histiocytes, 
with the highly atypical large lymphoma cells showing marked 
pleomorphism.
 [32]
 The nuclei of these cells are often horseshoe shaped or 
multilobed, and nucleoli are prominent. Cells indistinguishable from 
Reed–Sternberg cells may be seen. The cytoplasm is abundant and 
eosinophilic. The undue prominence of the latter feature in some cases 
was one of the reasons for this lesion to be mistakenly placed in the 
category of malignant histiocytosis. ALCL can also simulate malignant 
melanoma, undifferentiated carcinoma, and various types of soft tissue 
sarcoma.
 [33]
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MARGINAL ZONE B-CELL LYMPHOMA:  
Marginal zone B – cell lymphoma is the generic term used in the 
REAL/WHO schemes to designate an increasingly larger family of low-
grade B-cell lymphomas comprised of a heterogeneous population of 
small B cells. The concept represents a grouping of entities that had been 
described separately, most of them at extranodal sites.
[34]
 There appears to 
be considerable clinical, morphologic, and immunohistochemical overlap 
among the three entities (extranodal, nodal, and splenic).
[35]
 
Consequently, the proposal has been made that they represent a related 
family of neoplasms showing morphologic evidence of differentiation 
into cells of marginal zone type.
[36,37]
 A corollary of this proposal is that 
the various clinical syndromes may be the result of the homing pattern of 
the specific neoplastic clone.
[34]
 The proposal has been generally 
accepted, although it has been pointed out that important clinical and 
molecular genetic differences among the subgroups and even within a 
given subgroup exist.
[38,39,40]
 
NODAL MARGINAL ZONE LYMPHOMA:  
Tumors composed of small to medium-sized lymphocytes with 
round or slightly indented nuclei and abundant clear cytoplasm, usually 
located in lymph nodes, and hence called as nodal marginal zone 
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Lymphoma.
[41]
 The tumor cells have been regarded as the neoplastic 
counterpart of the monocytoid B lymphocytes found in lymph node 
sinuses in toxoplasmosis and other reactive disorders
[42]
 Plasmacytoid 
features are prominent in some cases. The pattern of involvement is 
predominantly sinusoidal and interfollicular,
 [43]
 but cases have been seen 
with ‘follicular colonization’ and with ‘floral’ features.[44] Clinically, the 
disease is more common in women, and can be localized or generalized at 
presentation.
[45]
 
EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED 
LYMPHOID TISSUE (KNOWN AS MALT LYMPHOMA ):  
This is a neoplasm in which the cell population – all of small size – 
has been described as including small round lymphocytes, monocytoid B 
cells, cells with slightly irregular nuclei (centrocyte-like), plasmacytoid 
cells, and plasma cells)
[46]
. This tumor was originally described at 
extranodal sites in relation to mucosae or glandular epithelia, such as 
gastrointestinal tract, salivary and lacrimal glands, lung, thyroid, 
conjunctiva, bladder, and skin. It characteristically remains localized for a 
long time and has a tendency to relapse in the same or other epithelium-
containing extranodal sites. It is now believed that many of the extranodal 
processes described years ago as pseudolymphomas of the lung, stomach, 
skin, and other sites are examples of this process. Patients may suffer 
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from autoimmune disorders such as Sjögren disease and Hashimoto 
thyroiditis. 
           Extranodal marginal zone lymphoma shows clonal rearrangements 
of the immunoglobulin genes. The variable region of the immunoglobulin 
heavy chain gene is hypermutated, supporting a postgerminal center stage 
of differentiation.
 [47]
 There are usually no rearrangements of the CCND1, 
BCL2, and BCL6 genes. 
         This lymphoma type exhibits distinctive chromosomal 
translocations involving API2-MALT1, IGH-MALT1, BCL10-IGH, and 
FOXP1-IGH fusion genes, respectively, and being mutually 
exclusive.
[48,49]
 The relative frequencies of these translocations in the 
various anatomic sites are highly variable. For example, API2-MALT1 
occurs predominantly in the gastrointestinal tract and lung; IGH-MALT1 
in the salivary gland, ocular adnexa and skin; and FOXP1-IGH in the 
thyroid and ocular adnexa.
[49,50,51]
BCL10-IGH translocation is very 
rare.
[49]
 Since the chromosomal translocations are specific for extranodal 
marginal zone lymphoma, their demonstration, such as by FISH or RT-
PCR, can aid in diagnosis and classification, with the caveat that such 
translocations are found in only about 30% of the cases.
[49,50,52]
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SPLENIC MARGINAL ZONE LYMPHOMA: 
 Cases of lymphoma involving the marginal zone of the spleen 
have been reported, sometimes in association with bone marrow and 
peripheral blood involvement.
 [53, 54]
  The disease is probably related if not 
identical to that reported under the term ‘splenic lymphoma with villous 
lymphocytes’ 
Extranodal marginal zone lymphoma associated with the 
distinctive chromosomal translocations are not found in splenic marginal 
zone lymphoma.
[55,56]
 Various chromosomal abnormalities have been 
reported, with complete or partial trisomy 3q being the commonest but 
not specific.
[57,58,59] 
 On the other hand, deletion or translocation involving 
7q32, found in 40% of cases, is a characteristic chromosomal 
aberration.
[57,59] 
 Microarray analysis shows that the expression of three 
genes (ILF1, SENATAXIN, CD40) can help distinguish splenic marginal 
zone lymphoma from other low-grade B-cell lymphomas.
[60] 
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MANTLE CELL LYMPHOMA:  
Mantle cell lymphoma is a rare lymphoid neoplasm which 
constitutes about 7 to 9% with male preponderance. Unlike other forms of 
GI lymphoma, it presents as polypoidal lesion and predominantly 
involving the small bowel.
 [61]
Histology shows the neoplasm composed of 
small or medium sized cells with irregular nuclear outline, condensed 
chromatin and little cytoplasm, and lymphoepithelial lesions are rare.
 [8] 
Immunophenotype shows the tumor cells positive for markers include 
CD5, CD20, CD79a, and cyclin D1.
 [8, 61]
 
ENTEROPATHY ASSOCIATED TYPE T-CELL LYMPHOMA 
(EATL):  
Enteropathy associated type T-cell lymphoma is an unusual 
lymphoma variant most commonly localised to the jejunum and 
ileum.
[62,63]
 A well defined relationship exists between celiac disease and 
the development of EATL, and compliance with a gluten free diet reduces 
the risk for lymphoma in these patients.
[62,64]
 Perforation is a frequent 
complication of EATL. Circumferential ulceration of the mucosa is 
common with these tumours, and a heavy eosinophilic and histiocytic 
infiltrate may obscure tumour cells, which are generally blastic with 
prominent nucleoli.
 [65]
 Adjacent normal bowel demonstrates villous 
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atrophy and crypt hyperplasia. Tumour markers include CD3, CD4, CD8, 
and TIA-1.  
Lymphoproliferative disorder most commonly affects the 
immunocompromised children. It is an aggressive tumour hence requires 
intense therapy. Lymphoproliferative disorder is further classified into 
systemic, primary CNS lymphoma, body cavity based lymphoma such as 
primary effusion lymphoma. Systemic lymphoma was subclassified into 
nodal and extranodal type. Extranodal type includes GIT and CNS. 
          Other rare lymphoma affecting children are Follicular lymphoma, 
Mantle cell lymphoma, Malt lymphoma and nodal marginal zone 
lymphoma. Follicular lymphoma affecting children are usually localized 
when compared to adult type. It mainly affects cervical lymph node and 
tonsils. It rarely affects gastrointestinal tract, testis, kidney and parotid. 
The onset of prognosis in paediatric follicular lymphoma is good 
compared to adults. 
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HODGKIN’S LYMPHOMA:  
Hodgkin’s Lymphoma is extremely rare in GIT. Only 2 cases were 
found by Lervin et al in a review of 117 lymphomas of the GIT. The large 
majority of cases diagnosed in the past are examples of Non-Hodgkin’s 
lymphoma of either B or T cell type. Hodgkins lymphoma present as 
nodal disease, then splenic disease, and finally involving the bone 
marrow and other tissues in a stereotypic fashion. Histology is 
characterized by the presence of neoplastic Giant cells called as Reed 
Sternberg cells which are large cells of about 45micrometer in diameter 
with multiple nuclei each with a large inclusion like nucleolus about the 
size of small lymphocytes. Hodgkins disease are classified into Classical 
and nodular lymphocyte predominant type. 
            Classical lymphoma is the most commonly occurring disease and 
composed of four subtypes such as Nodular sclerosis which affects young 
children and involving neck node and mediastinum, Mixed Cellularity 
affects older adults, Lymphocyte rich more commonly affects men than 
women, Lymphocyte depletion is the least common type seen in old age 
group and affecting spleen, bone marrow, liver and abdominal lymph 
nodes. Lymphocyte depletion is associated with HIV. 
20 
 
Another type is Nodular lymphocyte – predominant Hodgkins 
disease accounts for 5% of patients and affects younger patients involving 
neck nodes. This type has higher risk of transformation into diffuse large 
B – cell Non Hodgkins lymphoma. 
  With the current protocols prognosis, tumor stage is the important 
prognostic factor than histological type. Cure rate of patients with stage I 
and stage II is 90%. The disease free survival with advanced stage is 
about 60- 70%. 
The risk factors for non-Hodgkin Lymphoma affecting children are 
body weight, physical activity and diet. Researchers have found some 
factors that may put children at increased risk includes  Age, gender, and 
race.  
In general, Non-Hodgkin lymphoma is rare in children, but it is 
more common in older children than in younger ones and also affects 
more common in boys than in girls and in white children than in black 
children. Weakened immune systems sometimes have been linked with a 
higher risk of Non Hodgkin lymphoma in children.  
Congenital (present at birth) immune deficiency syndromes such as 
genetic (inherited) syndromes can cause children to be born with an 
abnormal immune system. Along with an increased risk of serious 
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infections, these children also have a higher risk of developing non-
Hodgkin lymphoma. These syndromes include Wiskott-Aldrich 
syndrome, Severe combined immunodeficiency syndrome (SCID), 
Ataxia-telangiectasia, Common variable immunodeficiency, Bloom 
syndrome, X-linked lymphoproliferative syndrome. 
Children who have received organ transplants are treated with 
drugs that weaken their immune system to prevent it from attacking the 
new organs. These children have an increased risk of developing non-
Hodgkin lymphoma that is almost always caused by Epstein-Barr virus 
infection. EBV has been linked with about 90% of Burkitt lymphomas in 
Africa.  
  Radiation exposure may be a minor risk factor in childhood non-
Hodgkin lymphoma.  Survivors of atomic bombs and nuclear reactor 
accidents have an increased risk of developing of non-Hodgkin 
lymphoma.  
With the current protocols prognosis, tumor stage is the important 
prognostic factor than histological type. Cure rate of patients with stage I 
and stage II is 90%. The disease free survival with advanced stage is 
about 60- 70%. 
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DIAGNOSIS: 
Patients present with gastrointestinal lymphoma are investigated 
with the following parameters including clinical history such as 
abdominal pain, mass, vomiting, diarrhoea, constipation, intestinal 
obstruction/intussusception and nodal involvement. A laboratory 
investigation includes complete blood count, peripheral smear, Bone 
marrow aspiration study, serum LDH, uric acid estimation and 
radiological examination of abdomen and pelvis. 
NHL is a rapidly growing neoplasm and so rapid detection is 
essential. Selection of appropriate mass or node for histological material 
is important. Histology remains the primary means for definitive 
diagnosis and should be supplemented if possible with immunophenotype 
and cytogenetic studies. 
DIFFERENTIAL DIAGNOSIS: 
Lymphoma is to be differentiated from other Small round cell 
tumour showing similar monotonous population of cells such as; 
1. Neuroblastoma – small round cells arranged in sheets, Homer 
wright rosettes or pseudorosettes are seen which shows central collection 
of neuropil surrounded by a mantle of neuroblasts. 
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2. The Ewing family of tumours – composed of small dark cells 
and large pale cells arranged in rossete which shows positive  for 
vimentin and CD99. 
3. Rhabdomyosarcoma – small round cells with cell condensation 
under the surface epithelium forming cambium layer. Tumour cells are 
positive for myogenin and desmin. 
4. Desmoplastic small-round-cell tumour- malignant small round 
cells arranged in nested pattern in desmoplastic stroma. 
Immunophenotype shows positive for vimentin and cytokeratin. 
All small round tumors are difficult to diagnose by light 
microscopy. An accurate diagnosis of these tumors has become 
increasingly crucial, as disparate approaches to therapy are used for 
distinct tumour types. Hence IHC and molecular genetics play a major 
role to overcome the difficulties in diagnosis for treatment of patients. 
PROLIFERATIVE MARKER 
Ki-67 is also known as MKI67, a protein encoded by the MKI67 
gene. Ki-67 marker was used as a proliferative marker to assess grading 
and prognostic significance. Ki-67 is a nuclear protein antigen present 
usually in active part of cell cycle in all proliferating cells. 
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Scoring of Ki-67 proliferative index is done by counting the 
number of positive lymphoma cells expressing brown colored nuclear Ki-
67 from the total number of malignant lymphoid cells. 1000 cells are 
counted in high power view showing maximum proliferative area. For 
estimating the proliferating cells, both weakly and strongly stained nuclei 
are included. 
Ki-67 are detected by immunohistochemistry and the other 
methods  of  detection  are by Western blot analysis and 
immunofluorescence. The  various  other  markers  of  proliferation  
include  AgNOR  staining, PCNA  and  Topoisomerase  II.   
IMMUNOHISTOCHEMISTRY:  
 Albert  Coons  et  al  in  1941  first introduced  labeled  antibodies  
directly  with fluorescent  isocyanate.  Nakane  and  Pierce  et  al  in  
1966, introduced  indirect labeling technique in which unlabeled antibody  
which is followed by second antibody or substrate. Various stages of 
development of Immunohistochemistry include peroxidase– 
antiperoxidase method (1970), alkaline phosphatase labeling (1971), 
avidin biotin method (1977) and two layer dextrin polymer technique 
(1993). 
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ANTIGEN RETRIEVAL:   
 Antigen  retrieval  can  be  done  by  the  following  different  
techniques  to unmask the antigenic determinants of fixed tissue sections.  
 1. Proteolytic enzyme digestion  
 2. Microwave antigen retrieval  
 3. Pressure cooker antigen retrieval  
 4. Microwave and trypsin antigen retrieval  
PROTEOLYTIC ENZYME DIGESTION:  
 Huank  et  al  in  1976  introduced  this  technique  to  breakdown  
formalin cross   linkages   to unmask  the  antigen  determinants.  The 
most commonly used enzymes include trypsin and proteinase. The 
disadvantages include over digestion, under digestion and antigen 
destruction.  
MICROWAVE ANTIGEN RETRIEVAL:  
 This  is  a  new  technique  most  commonly  used  in  current  
practice. Microwave oven heating involves boiling formalin fixed 
paraffin sections  in various  buffers  for  rapid  and  uniform  heating.  
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Antibodies against Ki67 and MIB-1 work well after heat pretreatment in 
this method. 
PRESSURE COOKER ANTIGEN RETRIEVAL:  
 Miller  et  al  in  1995  compared  and  proved  that  pressure  
cooking  method  has fewer  inconsistencies,  less  time  consuming  and  
can  be  used  to  retrieve  large number of slides than in microwave 
method. 
 
PITFALLS OF HEAT PRETREATMENT:  
 Drying of  sections  at  any  stage  after  heat  pretreatment  
destroys antigenicity.  Nuclear details are damaged in poorly fixed  
tissues.  Fibers and Fatty tissues tend to detach from slides while  heating.  
Not all  antigens  are retrieved by heat pretreatment and also some 
antigens like PGP 9.5 show altered staining pattern.  
DETECTION SYSTEMS:  
 After  addition  of  specific  antibodies  to  the  antigens,  next  step  
is  to visualize the  antigen  antibody  reaction  complex.  The methods 
employed are direct and indirect methods.   
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     In  the  direct  method,  primary  antibody  is  directly  conjugated  
with  the label. Most commonly used labels are flouro-chrome, horse 
radish peroxidase and alkaline  phosphatase.  Indirect method is  a  two-
step  method  in  which labeled  secondary  antibody  reacts  with  
primary  antibody  bound  to  specific antigen.  The use of peroxidase 
enzyme complex or avidin biotin complex further increases the sensitivity 
of immunohistochemical stains. In 1993, Pluzek et al introduced 
enhanced polymer one step staining, in which large numbers of primary 
antibody and peroxidase enzymes are attached to dextran polymer back 
bone. This is the rapid and sensitive method. Dextran  polymer  conjugate  
two  step  visualization  system  is  based  on dextran technology in Epos 
system. This method has greater sensitivity and is less time consuming.
 
 
 
 
 
MATERIALS AND 
METHODS
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MATERIALS AND METHODS 
 This study is a retrospective descriptive study of Extranodal 
Gastrointestinal Lymphoma conducted  in  the  Institute  of  Child Health, 
Egmore,  Madras Medical College, Dept. of Pathology, Chennai  during  
the  period  between January 2007 and December 2011.   
A  total  of   6300  cases  were  submitted  to  our  department  
during  the period  January 2007 – December  2011  for  histopathological  
examination . Total number of GI specimens received was 2834. Only 30 
of these specimens showed positive for GI Lymphoma showing an 
overall percentage of 0.48. The total number of non- neoplastic, benign 
and malignant cases were 2784,12 and 38  respectively. Thus the 
distribution of non-neoplastic lesions was 98.2 %, of benign tumors were 
0.42% and of malignant tumors were 1.34% among the GI specimens.   
SOURCE OF DATA 
The  GIT lymphoma cases  reported  in  resected  specimens 
received in the Institute of  child  Health, Egmore, Pathology department, 
between January 2007  to  December  2011  from  the  Department  of 
Paediatric Surgery, Govt. General Hospital. A total of 30 resected 
specimens were received during this period.   
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Inclusion criteria  
All the GI lymphoma  cases  reported  in  resected specimens with 
age group between 0 to 12years, irrespective of sex were included for the 
study.  
Exclusion criteria  
 Age more than 13 years. 
 Non neoplastic lesions and benign tumors of GIT 
 Lymphoma of Mediastinal adenopathy, Peripheral adenopathy, 
Testicular and Parapharyngeal mass.  
METHOD OF DATA COLLECTION 
           Detailed  history  of  the  cases  regarding  age,  sex,  history,  type  
of procedure, details of gross characteristics were obtained for all the 30 
resected  GIT cases reported during the period  of  study  from  Paediatric 
Surgical  pathology  records.  Hematoxylin and Eosin stained 4 microns 
thick sections of the paraffin tissue blocks of resected specimens were 
reviewed.  
 The  following  clinical  and  pathological  parameters  were 
evaluated: Age (0-12years), gender, tumour size (<5 and >5cm), tumour 
location (Ileum, Caecum, ascending colon, liver and Spleen),  
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macroscopic  appearance. Lymphomas were classified based on St. Jude 
Staging. Microscopic appearances were divided into B cell and T cell 
type. 
Lymphoma staging was done according to the standards of St. Jude 
stage (2010) (Annexure – II).  
30 cases of GI Lymphoma of varying grades were randomly 
selected  from  the  total  cases  and  their  representative  formalin  fixed  
paraffin embedded tissue samples were subjected to 
immunohistochemistry for a panel of 4 markers – CD3,CD20,CD45 and 
Ki-67. 
IMMUNOHISTOCHEMICAL EVALUATION 
Immuohistochemical  analysis  of  a  panel  of  markers  including  
CD3,CD20,CD45  and Ki-67  were  done  in  paraffin  embedded  tissue  
samples  using  Super-sensitive polymer  HRP  system  based  on  non-
biotin  polymeric  technology.  4 microns thick sections are cut from 
paraffin embedded tissue samples were transferred onto gelatin coated 
slides. Heat induced antigen retrieval was done. The antigen was  bound  
with mouse  monoclonal  antibody  (Biogenex)  against CD3,CD20,CD45  
protein and  Ki - 67  protein and  then  detected  by the addition  of  
secondary  antibody conjugated  with  horse  radish  peroxidase-polymer  
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and  diaminobenzidine substrate.  A  step  by  step  procedure  of  
Immunohistochemistry  is  shown in Annexure IV. Antigen  Vendor  
Species(clone)  Dilution  Positive control CD3,CD20 and CD45  
BIOGENEX  Mouse  Ready to use  GIT Ki - 67  BIOGENEX  Mouse  
Ready to use  GIT. 
INTERPRETATION & SCORING SYSTEM 
The  immunohistochemically  stained  slides  were  analyzed  for  
the presence  of  reaction,  cellular  localization,  percentage  of  cells  
stained  and intensity of reaction. Nuclear staining was assessed for   
Ki - 67. Cytoplasmic staining was assessed for CD3, CD20 and CD45. 
T Cell type tumor cells shows CD3 immuno-reactivity was 
assessed asbeing intense cytoplasmic staining  positive. CD20 intense 
cytoplasmic positive staining into B cell type. CD45 shows intense 
cytoplasmic positive staining for  both T and B cell type. 
The Ki-67 labeling index was determined by counting at high 
power view 1000 tumour cell nuclei in areas of the section. The Ki-67 
labeling  index  for  the  30 tumours  ranged  from  0 %  to  98% with  a  
mean labeling index of 58.4%.   
Labeling index greater than 60% indicates High Ki-67.  Labeling 
index lesser than 60% indicates Low Ki - 67. 
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STATISTICAL ANALYSIS 
Data was analysed using SSPS version 11.5 which consisted of 
computing the frequency counts and percentages for qualitative variables 
and mean for the quantitative variables.  Numerical data were expressed 
as mean with standard deviation. Categorical variable were expressed as 
frequency and percentage. 
          The Overall survival was calculated from the date of completion of  
chemotherapy to the date of last follow up or death. For those patients 
who attained complete remission, the disease free survival for those 
patients was calculated from date of  of completion of chemotherapy till 
the date of relapse . 
            Survival analysis was calculated using Kaplan-Meier test and 
presented as cumulative survival rates. Comparison between two survival 
curves was done using Breslow test. A probability (P-value) less than 
0.05 was considered statistically significant. 
The  expression  of  CD3,CD20,CD45  and  the  Ki  –  67  labeling  
index  was  correlated  with clinico  –  pathological  factors  like  age,  
gender,  tumour  site,  tumour configuration, size,  histological types, 
histological grade, depth of  infiltration,  using the Pearsons Chi –Square  
test. 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION 
AND RESULTS
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OBSERVATION AND RESULTS 
In the study period of 60 months from January 2007 to December 
2011, a total  of  6300  specimens  were  received  in  the  Institute of 
Child health, Egmore, Department of Pathology, Madras Medical College  
for histological examination. Total number of GI resected specimens 
received was 2834. Of these GI Lymphoma accounted for 30 with a 
percentage of  0.48%. The total number of non- neoplastic, benign and 
malignant cases was 2784,12 and 38  respectively. Thus the distribution 
of non-neoplastic lesions was 98.2 %, of benign tumors were 0.42% and 
of malignant tumors were 1.34% among the GI specimens.   
Among the study samples, 15 cases (50.0%) had tumor less than 5 
cm in size and another 15 cases (50%) were 5cm or more in size. (Table 1 
& Chart 1). 
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                                TABLE – 1 
            AGE WISE DISTRIBUTION OF PAEDIATRIC                
                   GASTROINTESTINAL LYMPHOMA 
AGE No. of cases Percent % Cumulative Percent % 
1-5 yr 15 50.0 50.0 
> 5 yr 15 50.0 100.0 
Total 30 100.0  
 
Table shows age distribution of the collected samples.  Peak age 
distribution is seen in 5-9 years of age as shown in Table 2 (Chart 2). 
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TABLE - 2 
AGE WISE DISTRIBUTION OF  PAEDIATRIC GI LYMPHOMA 
AGE No of cases Percent% 
Cumulative 
percent% 
1-4 years 11 36.7 36.7 
5-9 years 14 46.7 83.3 
10-14 
years 
5 16.7 100 
Total 30 100  
 
Gastrointestinal lymphoma had a peak incidence in the age group 
of  5-9 years. Among the 30 cases, 21 (70%) cases were reported in males 
and 9 (30%) cases were reported in females as shown in  (Table 3 & 
Chart 2) 
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TABLE – 3 
 SEX WISE DISTRIBUTION OF PAEDIATRIC 
GASTROINTESTINAL LYMPHOMA 
AGE No. of cases Percent% cumulative percent% 
Female 9 30 30 
Male 21 70 100 
Total 30 100  
 
In our sample study the clinical features associated with paediatric 
GI lymphoma shown in Table 4 
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TABLE – 4 
DISTRIBUTION OF SYMPTOMS IN PAEDIATRIC GI 
LYMPHOMA 
Symptoms No. of cases Percent % 
Abdominal pain 23 76.7 
Abdominal swelling 21 70.0 
Vomiting 12 40.0 
Constipation 5 16.7 
Obstruction/Intussusception 6 20.0 
 
Among the 30 cases, 20 (66.7%) of cases involved the Small 
intestine (Ileum), 2 (6.7%) cases involved the Large intestine (Caecum), 6 
(20.0%) cases involved both (Ileocaecal region) and 2 (6.7%) cases were 
in Spleen as shown in Table 5.  
 
 
 
 
 
5. 
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TABLE – 5 
SITE WISE DISTRIBUTION OF PAEDIATRIC 
GASTROINTESTINAL LYMPHOMA 
Site No of cases Percent % cumulative percent % 
Small 
intestine 
20 66.7 66.7 
Large 
intestine 
2 6.7 73.3 
Both 6 20.0 93.3 
Spleen 2 6.7 100.0 
Total 30 100.0  
 
The distribution of tumor Localisation and Extension in 
Gastrointestinal Lymphoma is shown in Table 6 & Chart 4 
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TABLE – 6 
LOCALISED/EXTENSIVE DISTRIBUTION OF PAEDIATRIC 
GASTROINTESTINAL LYMPHOMA 
Tumour extent No. of cases Percent % Cumulative percent % 
Extensive 5 16.7 16.7 
Localised 25 83.3 100.0 
Total 30 100.0  
 
The distribution of various Histological subtypes in GI Lymphoma 
in our sample size are Grouped into Burkitt’s in 10 cases (33.3%) and 
others in 20 cases (66.7%). Others include Diffuse Large B Cell 
Lymphoma, Anaplastic Lymphoma, Lymphoblastic Lymphoma, Malt 
type Lymphoma and Splenic Lymphoma are shown in Table 7 & Chart 6. 
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TABLE – 7 
DISTRIBUTION OF HISTOLOGICAL SUBTYPES IN 
PAEDIATRIC GASTROINTESTINAL  LYMPHOMA 
Histological type 
No. of 
cases 
Percent % Cumulative percent % 
Burkitt 10 33.3 33.3 
Others: Maltoma 
DLBCL 
Anaplastic lymphoma 
LL 
Hodgkins lymphoma 
9 30.0 63.3 
7 23.3 86.6 
1 3.3 89.9 
1 3.3 93.3 
2 6.7 100.0 
Total 30 100  
 
In the present study, 22 cases (73.3%) belonged to stage IIE and 8 
cases (26.7%) belonged to stage IVE. (Table 8 & Chart 7). 
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TABLE - 8 
DISTRIBUTION OF PAEDIATRIC GASTROINTESTINAL 
LYMPHOMA ACCORDING  TO ST.JUDE STAGE 
Stage No of cases 
Percent 
% 
Cumulative 
percent % 
IIE 22 73.3 73.3 
IVE 8 26.7 100.0 
Total 30 100.0  
 
Response to Chemotherapy was noted for 25 cases (83.3%) and no 
response to Chemotherapy noted in 5 cases (16.7%).  (TABLE 9).  
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TABLE – 9 
DISTRIBUTION OF CASES RESPONSE TO 
CHEMOTHERAPY(CT) IN PAEDIATRIC GI LYMPHOMA 
Response to CT No. of cases Percent % 
Cumulative 
percent % 
Yes 25 83.3 83.3 
No 5 16.7 100.0 
Total 30 100.0  
 
In the study Chemotherapy complication was found in 2 cases 
(6.7%) and no chemotherapy complication was found in 28 cases (93.3%) 
as shown in (Table 10). 
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TABLE – 10 
DISTRIBUTION OF CASES OF CHEMOTHERAPY 
COMPLICATION IN GI LYMPHOMA 
Chemotherapy 
complication 
No. of cases 
Percent 
% 
Cumulative 
percent % 
Yes 2 6.7 6.7 
No 28 93.3 100 
Total 30 100  
 
In the study, the statistics of  patient survive with in GI lymphoma 
is shown in (Table11 & Chart 8). 
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TABLE – 11 
DISTRIBUTION OF SURVIVAL AND DEATH RATE OF 
PAEDIATRIC  GI LYMPHOMA 
Survival No. of cases Percent % 
Cumulative 
percent % 
Survival 25 83.3 83.3 
Death 5 16.7 100.0 
Total 30 100.0  
 
In our study,  bone marrow involvement was observed in 5 cases 
(16.7%) and  no bone marrow involvement in 25 cases (83.3%) as shown 
in (Table 12). 
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TABLE – 12 
DISTRIBUTION OF BONE MARROW INFILTRATION(BMI) IN 
PAEDIATRIC  GI  LYMPHOMA 
 
Bone marrow infiltration No. of cases Percent % 
Cumulative 
percent % 
Yes 5 16.7 16.7 
No 25 83.3 100.0 
Total 30 100.0  
 
RESULTS OF IMMUNOHISTOCHEMICAL STUDIES : 
      A total of 30cases, with varying type and stage were selected and 
subjected to immunohistochemical(IHC) analysis with a panel of  4 
markers – CD3,CD20,CD45 and Ki-67. The result of IHC study was 
shown in (TABLE 13). 
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TABLE – 13 
RESULTS OF IHC  OBSERVED FOR 30 CASES 
IHC Postive(%) Negative(%) 
CD20 28(93.3) 2(6.7) 
CD45 30(100) 0(0.0) 
CD3 0(0.0) 30(100) 
Ki67   <60 
           >60 
21(70.0) 
17(56.7) 
2(6.7) 
 
 Among  the 30 cases, there were 21 males (70%) and 9 females 
(30%). Ages ranged between 2 and 11 with a mean of 6.10.  There were 
15 cases (50%) below 5 years of age and 15 cases (50%) more than 5 
years. The tumor was located in the Ileum in 20 cases (66.7%), caecum  
in 2 cases (6.7%), ileocaecal region in 6 cases (20%) and spleen in  
2 cases (6.7%). 
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Histological subtypes: 
Ten cases (33.3%) were of the Burkitt type, 9 cases (30.0%) were 
of the Malt type, 7 cases (23.3%) were DLBCL type, 1 case (3.3%) was  
anaplastic type,1 case (3.3%) was lymphoblastic type  and 2 cases (6.7%) 
belonged to splenic lymphoma. 
Among the final study group, 22 (73.3%) cases belonged to stage 
IIE, 8 (26.7%) cases belonged to stage IVE as shown in  (Table 14). 
 
 
 
 
 
 
 
 
 
48 
 
 
TABLE - 14 
DISTRIBUTION OF GASTRO INTESTINAL LYMPHOMA 
AMONG THE VARIOUS CLINICOPATHOLOGICAL GROUPS 
FOR THE IHC STUDY (30 CASES) 
Clinicopathological factors No. of cases 
Age <5yrs 
>5yrs 
15(50.0%) 
15(50.0%) 
Gender Male 
Female 
21(70.o%) 
9(30.0%) 
Tumor site Small intestine 
Large intestine 
Both 
Spleen 
20(66.7%) 
2(6.7%) 
6(20.0%) 
2(6.7%) 
Tumor extent Localised 
Extensive 
25(83.3%) 
5(16.7%) 
BM infiltration Yes 
No 
5(16.7%) 
25(83.3%) 
Histological type Burkitt  
Others : Maltoma                  
            DLBCL 
           Anaplastic type   
    Lymphoblastic type 
  Hodgkins lymphoma 
10(33.3%) 
9(30.0%) 
7(23.3%) 
1(3.3%) 
1(3.3%) 
2(6.7%) 
Stage IIE 
IVE 
25(83.3%) 
5(16.7%) 
Surgical resection Complete resection 
Partial resection 
30(100.0%) 
0(0.0%) 
Preconditioning CT Yes 
No 
0(0.0%) 
30(100.0%) 
Response to CT Yes 
No 
25(83.3%) 
5(16.7%) 
CT complication Yes 
No 
2(6.7%) 
28(93.3%) 
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 In our study sample correlation of age was done with survival of 
patients. 13 cases (86.7%) survived less than 5 years and 12 cases 
(80.0%) survived more than 5 years as shown in (Table 15 & Chart 9).  
TABLE – 15 
CORRELATION WITH AGE AND SURVIVAL RATE OF  
PAEDIATRIC GI LYMPHOMA 
Age 
SURVIVAL ANALYSIS 
TOTAL 
Pearson 
Chisquare 
test 
Survival Death 
<5 years     
 
 
 
 
 
 
0.500 
No of cases 13 2 15 
% within age 86.7% 13.3% 100% 
% within survival 52.0% 40.0% 50.0% 
>5years    
No of cases 12 3 15 
% within age 80.0% 20.0% 100% 
% within survival 48.0% 60.0% 50.0% 
TOTAL    
No of cases 25 5 30 
% within age 83.3% 16.7% 100% 
% within survival 100% 100% 100% 
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In our study, sample correlation of sex was done with survival of 
patients. 9 cases (36.0%) show survival in female child.16 cases (64.0%) 
of survival in male child as shown in Table 16. 
TABLE  - 16 
CORRELATION WITH SEX AND SURVIVAL RATE OF  
PAEDIATRIC GI LYMPHOMA 
Sex 
SURVIVAL ANALYSIS 
TOTAL 
Pearson 
Chisquare 
test 
Survival Death 
Female     
 
 
 
 
 
 
0.143 
No of cases 9 0 9 
% within sex 100% 0.0% 100% 
% within survival 36.0% 0.0% 30.0% 
Male    
No of cases 16 5 21 
% within sex 76.2% 23.8% 100% 
% within survival 64.0% 100% 70.0% 
TOTAL    
No of cases 25 5 30 
% within sex 83.3% 16.7% 100% 
% within survival 100% 100% 100% 
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This study shows BM infiltration in 5 cases with death rate of 
about 16.7% as shown in Table 17. 
TABLE – 17 
CORRELATION OF CASES OF BM INFILTRATION WITH 
SURVIVAL RATE OF PAEDIATRIC GI LYMPHOMA 
BM infiltration(BMI) 
SURVIVAL ANALYSIS 
TOTAL 
Pearson 
Chisquare 
test 
Survival Death 
BM infiltration present     
 
 
 
 
 
 
<0.001 
                No of cases 0 5 5 
 % within BMI  0.0% 100% 100% 
 % within survival 0.0% 100% 16.7% 
No BMI    
                No of cases 25 0 25 
 % within BMI  100% 0.0% 100% 
 % within survival 100% 0.0% 83.3% 
TOTAL    
                No of cases 25 5 30 
 % within BMI  83.3% 16.7% 100% 
 % within survival 100% 100% 100% 
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In this study shows involvement of small intestine in 20 cases and 
percentage within survival in 3 death case is 60% shown in Table 18. 
TABLE – 18 
CORRELATIONS WITH SITE AND SURVIVAL RATE OF 
PAEDIATRIC GI LYMPHOMA 
 SURVIVAL ANALYSIS TOTAL Pearson 
Chisquare test Survival Death 
Small intestine     
 
 
 
 
 
 
0.564 
 
 
 
No of cases 17 3 20 
% within site 85.0% 15.0% 100% 
% within survival 68.0% 60.0% 66.7% 
Large intestine    
No of cases 1 1 2 
% within site 50.0% 50.0% 100% 
% within survival 4.0% 20.0% 6.7% 
Both    
No of cases 5 1 6 
% within site 83.3% 16.7% 100% 
% within survival 20.0% 20.0% 20.0% 
Spleen    
No of cases 2 0 2 
% within site 100% 0.0% 100% 
% within survival 8.0% 0.0% 6.7% 
Total    
No of cases 25 5 30 
% within site 83.3% 16.7% 100% 
% within survival 100% 100% 100% 
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In this study 5 cases showed Extensive involvement and percentage 
within survival of 16.7% as shown in Table 19. 
TABLE – 19 
CORRELATION OF DISTRIBUTION OF TUMOR EXTENT WITH 
SURVIVAL RATE OF PAEDIATRIC GI LYMPHOMA 
 
Tumor extent 
SURVIVAL ANALYSIS 
TOTAL 
Pearson 
Chisquare 
test 
Survival Death 
Extensive     
 
 
 
 
 
 
<0.001 
No of cases 0 5 5 
% within extent 0.0% 100% 100% 
% within survival 0.0% 100% 16.7% 
Localised    
No of cases 25 0 25 
% within extent 100% 0.0% 100% 
% within survival 100% 0.0% 83.3% 
TOTAL    
No of cases 25 5 30 
% within extent 83.3% 16.7% 100% 
% within survival 100% 100% 100% 
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In this study,  pathological subtype Burkitt Lymphoma shows 4 
cases of Death and percentage within survival rate of  80.0% as shown in 
Table 20. 
TABLE – 20 
CORRELATION OF PATHOLOGICAL SUBTYPE WITH 
SURVIVAL RATE OF PAEDIATRIC GI LYMPHOMA 
Histological type SURVIVAL ANALYSIS TOTAL Pearson 
Chisquare test Survival Death 
Burkitt’s     
 
 
 
 
 
 
0.031 
No of cases 6 4 10 
% within type 60.0% 40.0% 100% 
% within survival 24.0% 80.0% 33.3% 
Others    
No of cases 19 1 20 
% within type 95.0% 5.0% 100% 
% within survival 76.0% 20.0% 66.7% 
TOTAL    
No of cases 25 5 30 
% within type 83.3% 16.7% 100% 
% within survival 100% 100% 100% 
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In this study, sample of correlation of tumor stage with survival 
shows  8 cases with Stage IV E and  percentage within survival in 5 cases 
of  26.7%  as shown in (Table 21& Chart 10) 
TABLE – 21 
CORRELATION OF TUMOR STAGE WITH SURVIVAL RATE 
OF PAEDIATRIC GI LYMPHOMA 
 
Stage 
SURVIVAL ANALYSIS 
TOTAL 
Pearson 
Chisquare 
test 
Survival Death 
Stage IIE    
 
 
 
 
 
 
 
<0.001 
No of cases 22 0 22 
% within stage 100% 0.0% 100% 
% within survival 88.0% 0.0% 73.3% 
Stage IVE    
No of cases 3 5 8 
% within stage 37.5% 62.5% 100% 
% within survival 12.0% 100% 26.7% 
TOTAL    
No of cases 25 5 30 
% within stage 83.3% 16.7% 100% 
% within survival 100% 100% 100% 
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In this study, sample of correlation of Ki-67 labeling index with 
survival rate shows 5 cases of death present in high Ki-67 LI and shows 
percentage within Ki-67 of 29.4% as shown in (Table 22 & Chart11). 
TABLE – 22 
CORRELATION OF KI-67 LABELLING INDEX WITH 
SURVIVAL RATE OF PAEDIATRIC  GI LYMPHOMA 
Ki-67 
SURVIVAL ANALYSIS 
TOTAL 
Pearson 
Chisquare 
test 
Survival Death 
Mild    
 
 
 
 
 
 
 
0.049 
No of cases 7 0 7 
% within Ki67 100% 0.0% 100% 
% within survival 28.0% 0.0% 23.3% 
Moderate    
No of cases 6 0 6 
% within Ki67 100% 0.0% 100% 
% within survival 24.0% 0.0% 20.0% 
Severe  Zw  
No of cases 12 5 17 
% within Ki67 70.6% 29.4% 100% 
% within survival 48.0% 100% 56.7% 
TOTAL    
No of cases 25 5 30 
% within Ki67 83.3% 16.7% 100% 
% within survival 100% 100% 100% 
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In this study sample correlation of response to CT with Survival 
was done. 5 cases of death with no response to Chemotherapy and 
percentage within survival of 16.7% were seen as shown in Table 23. 
TABLE – 23 
CORRELATION OF RESPONSE TO CHEMOTHERAPY WITH 
SURVIVAL  RATE OF PAEDIATRIC GI LYMPHOMA 
 
Response to 
chemotherapy(CT) 
SURVIVAL ANALYSIS 
TOTAL 
Pearson 
Chisquare 
test 
Survival Death 
Yes    
 
 
 
 
 
 
 
<0.001 
No of cases 0 5 5 
% within response to CT 0.0% 100% 100% 
% within survival 0.0% 100% 16.7% 
No    
No of cases 25 0 25 
% within response to CT 100% 0.0% 100% 
% within survival 100% 0.0% 83.3% 
TOTAL    
No of cases 25 5 30 
% within response to CT 83.3% 16.7% 100% 
% within survival 100% 100% 100% 
 
In this study, sample correlation of cases of CT complication with 
survival shows 2 cases with CT complication and percentage within 
survival of 40% as shown in (Table 24) 
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TABLE 24   
CORRELATION OF CASES OF CHEMOTHERAPY 
COMLPICATION WITH  SURVIVAL RATE OF PAEDIATRIC GI 
LYMPHOMA 
Chemotherapy(CT) 
complication 
SURVIVAL ANALYSIS 
TOTAL 
Pearson 
Chisquare 
test 
Survival Death 
Yes     
 
 
 
 
 
 
0.023 
No of cases 0 2 2 
% within  CT 
complication 
0.0% 100% 100% 
% within survival 0.0% 40.0% 6.7% 
No    
No of cases 25 3 28 
% within  CT 
complication 
89.3% 10.7% 100% 
% within survival 100% 60.0% 93.3% 
TOTAL    
No of cases 25 5 30 
% within  CT 
complication 
83.3% 16.7% 100% 
% within survival 100% 100% 100% 
 
Five mortality cases (16.7%) were reported, 3 of them died out of 
progressive disease on first line Chemotherapy and 2 cases with after 
relapse. 
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SURVIVAL ANALYSIS: 
The mean duration of follow-up was 26 months (range of 7 months 
to 67 months).  The Overall and disease free survival rates in our study 
were 83.3% and 89.2% respectively (FIG 1&2).  While calculating 
disease free survival those with progressive disease are non responders 
were not included. The correlation between the overall survival and 
various clinicopathological parameters had shown that no bone marrow 
infiltration (p <0.001), localised disease (p < 0.001), early stage disease 
(p < 0.001), non Burkitt type (p = 0.031), response to chemotherapy (p 
<0.001) and low Ki67 labeling index had statistically significantly 
influenced the overall survival. When the disease free survival was 
correlated with the same clinicopathological parameters, no bone marrow 
infiltration (p <0.001), localized disease (p <0.001), early stage (p 0.006) 
and response to chemotherapy (p <0.001) were found to have significant 
effect on disease free survival as shown in Table 25. 
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TABLE - 25  
OVERALL  AND  DISEASE  FREE SURVIVAL  ANALYSIS 
Variables Total 
60months 
Overall 
survival 
rate 
P value Result Total 
60months 
Overall 
survival rate 
P value Result 
All patients 30 83.3 28  28 89.2   
Age <5years 
>5years 
15 
15 
86.7 
80.0 
 
1.000 
NS 15 
13 
86.7 
92.3 
1.000 NS 
Gender- Male 
Female 
21 
9 
76.2 
100.0 
0.286 NS 19 
9 
84.2 
100.0 
0.530 NS 
Infil  NO 
BMI 
BMI 
25 
9 
100.0 
0.0 
<0.001 Sig 25 
3 
100.0 
0.0 
<0.001 Sig 
GIT   SI 
LI 
Both 
Spleen 
20 
2 
6 
2 
85.0 
50.0 
83.3 
100.0 
0.564 NS 19 
1 
6 
2 
89.5 
100.0 
83.3 
100.0 
0.900 NS 
Disease  
Local 
Extent 
25 
5 
100.0 
0.0 
<0.001 Sig 25 
3 
100.0 
0.0 
<0.001 Sig 
Histotype: 
Burkitt 
Others 
10 
20 
60.0 
95.0 
 
0.031 
 
 
Sig 
9 
19 
66.7 
100.0 
 
0.026 
 
Sig 
Stage       IIE 
IVE 
22 
8 
100.0 
37.5 
<0.001 Sig 22 
6 
100.0 
50.0 
0.006 Sig 
Response to 
CT 
YES 
NO 
 
25 
5 
 
100.0 
0.0 
 
<0.001 
 
Sig 
 
25 
3 
 
100.0 
0.0 
 
<0.001 
 
Sig 
 
CT 
complication 
YES 
NO 
 
2 
28 
 
0.0 
89.3 
 
0.023 
 
 
Sig 
 
- 
 
- 
 
- 
 
- 
Ki67  Low 
value 
High value 
13 
17 
100.0 
70.6 
 
0.04 
 
Sig 
13 
13 
 
100.0 
80.0 
 
 
0.226 
 
NS 
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FIG -1:   
OVERALL- SURVIVAL FUNCTION 
 
 
 
 
 
62 
 
 
 
FIG 2: 
SURVIVAL FUNCTION CHILDREN EXCLUDING     
           CHEMOTHERAPY COMPLICATIONS 
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Total number of cases in our study sample was 30, and all cases after 
surgery was treated with chemotherapy, there was no missing cases. The 
mean age group was 6.10 and age ranges from 3 to 11 years. Similarly, 
Ki-67 was done in all 30 cases. Maximum labeling index was seen in 
Burkitt’s lymphoma ranging from 80 to 90%, DLBCL  ranges from 40 to 
80% and for Hodgkin’s lymphoma is 0%. Hence the mean  
Ki-67 index is 58.50 as shown in (Table 26). 
 
TABLE - 26 
STATISTICAL DATA FOR AGE AND KI67 
 
Total 
no of 
cases 
Missing 
cases 
Mean Median 
Standard 
deviation 
Minimum Maximum 
AGE 30 0 6.10 5.50 2.48 3 11 
Ki-67 30 0 58.50 80.00 34.5 0.00 98.0 
 
30 0 58.50 80.0  34.5 0.0  98.0 
 
 
 
 
 
 
 
 
 
 
CHARTS
 
 
CHART 1   AGE WISE DISTRIBUTION OF CASES IN PAEDIATRIC  GI 
LYMPHOMA 
 
CHART 2 SEX WISE  DISTRIBUTION OF CASES IN PAEDIATRIC GI 
LYMPHOMA
 
 
CHART 3 SITE WISE DISTRIBUTION OF CASES OF 
PAEDIATRIC GI LYMPHOMA 
 
CHART 4 D ISTRIBUTION OF CASES OF TUMOUR EXTENT IN 
PAEDIATRIC GI LYMPHOMA 
 
 
 
CHART 5 FREQUENCY OF INVOLVEMENT OF BUTKITT YUMOR IN 
PAEDIATRIC  GI LYMPHOMA 
 
CHART 6 DISTRIBUTION OF HISTOLOGICAL SUBTYPE OF 
PAEDIATRIC GI LYMPHOMA 
 
 
 
 
CHART 7   STAGE WISE  DISTRIBUTION  OF PAEDIATRIC GI 
LYMPHOMA 
 
CHART 8   DISTRIBUTION OF SURVIVAL AND DEATH OF  PAEDIATRIC 
GI LYMPHOMA 
Frequency
Survival
Death
Total
25
5
30
 
 
 
CHART 9 CORRELATION OF AGE VS SURVIVAL OF PAEDIATRIC GI   
LYMPHOMA 
 
 
 
 
 
 
 
 
 
CHART 10  CORRELATION  BETWEEN STAGE AND SURVIVAL RATE 
OF PAEDIATRIC GI LYMPHOMA 
 
 
 
 
 
 
 
 
CHART 11 CORRELATION OF CASES OF KI67 LI WITH 
SURVIVAL RATE OF PAEDIATRIC GI LYMPHOMA 
 
 
 
 
 
 
 
 
 
                
 
 
 
                      
 
 
 
FIG 3.2  Cut surface in Ileum  
shows  grey white mass extending 
upto serosa. 
FIG  3.1 Cut surface – Grey 
white nodular mass in caecum 
 
FIG 3.3 External surface of 
Spleen - nodular  
FIG 3.4 Cut surface  of Spleen 
shows grey white multiple 
nodule. 
    GROSS SPECIMEN 
 
 
 
 
 
                   
 
 
 
 
                                
 
FIG 4.2   H&E Burkitt 
Lymphoma extending upto 
serosa X10  
FIG 4.1  H&E    
Burkitt  Lymphoma X10 
 
FIG 4.3  IHC X10  CD 20 
intense strong positivity. 
H&E – BURKITT LYMPHOMA 
IHC – BURKITT LYMPHOMA 
FIG 4.4 IHC X10 CD3 tumour 
cells shows negativity 
 
 
 
 
 
 
 
 
FIG 4.5 IHC X10 -CD45 tumour cells show strong positivity 
 IHC -BURKITT LYMPHOMA 
FIG 4.6  IHC X10 Ki67  tumour cells show  high Labeling index  
 
 
 
 
                          
 
 
 
 
           
 
 
FIG 5.2 H&E X10 Burkitt 
Lymphoma 
FIG 5.1 H&E X10 
Burkitt Lymphoma 
FIG 5.3 IHC X10  Burkitt 
lymphoma -Ki67 tumour cells 
show  high  labeling index 
positivity 
FIG 5.4 IHCX10 Burkitt 
lymphoma   CD45 shows 
Strong positivity 
BURKITT LYMPHOMA 
IHC – BURKITT LYMPHOMA 
 
 
 
 
 
                                                                                               
 
 
           
              
 
 
FIG 6.2 H&E X 10 Burkitt 
Lymphoma with starry sky 
pattern 
FIG 6.3 IHC X40  Burkitt 
lymphoma - CD20  strong 
positive 
FIG 6.1  H&E X10 Burkitt 
lymphoma 
BURKITT LYMPHOMA 
IHC – BURKITT LYMPHOMA 
FIG 6.4 IHC X10 Burkitt 
lymphoma - CD20 Strong 
positivity  
 
 
 
 
 
 
 
      
 
 
FIG 6.6  Burkitt lymphoma - IHC X10  Ki67  shows high 
index positive 
FIG 6.5 Burkitt lymphoma - IHC X40 CD45 strong  positive 
IHC – BURKITT LYMPHOMA 
 
 
 
 
             
 
    
                                                                                
       
 
 
FIG 7.1 H&E X10  Maltoma 
FIG 7.2 H&EX40  Malt 
lymphoma extends into 
lamina propria 
FIG 7.3 IHC X10  CD45  
Maltoma - Strong 
positivity 
FIG 7.4  IHC X10  Maltoma – 
Ki67  tumour cells show low 
labeling index  
IHC – MALTOMA  
H&E - MALTOMA 
 
 
 
 
               
 
 
 
 
     
 
 
FIG 8.3 IHC X40  Maltoma -
Ki67 low index positive 
FIG 8.1 H&E x10 Maltoma 
showing lymphoepithelial  
invasion 
FIG 8.2  H&E X40 Maltoma 
tumour cell showing 
lymphoepithelial invasion 
FIG 8.4 IHC X10 Maltoma – 
CD20 tumour cells show 
strong positive   
IHC –  MALTOMA 
H&E - MALTOMA 
 
 
 
                                                                                                        
                  
 
 
 
 
               
 
FIG 9.2 H&E X100 Diffuse large 
B  cell lymphoma . 
FIG 9.1 H&E X10  DLBCL in 
sheet like pattern 
FIG 9.3 IHC X10 DLBCL - 
CD20  shows strong positive 
IHC – DIFFUSE LARGE B CELL LYMPHOMA 
DIFFUSE LARGE CELL LYMPHOMA 
FIG 9.4 IHCX10  DLBCL – 
CD3  Negative 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 9.5 IHCX10 DLBCL- CD45 strong positive 
FIG 9.6 IHC X40 DLBCL - Ki67  high index positive 
IHC – DIFFUSE LARGE B CELL LYMPHOMA 
 
 
 
 
         
 
        
              
 
 
 
FIG 10.1   H&E X10  
Lymphoblastic lymphoma 
FIG 10.4 IHCX10 Lymphoblastic 
lymphoma- CD20 Strong positive 
FIG 10.3  IHCX10  
Lymphoblastic lymphoma- 
Ki67 High index positive 
FIG 10.2  H&E X40  
Lymphoblastic lymphoma 
LYMPHOBLASTIC LYMPHOMA 
 
 
  
            
 
 
 
     
 
 
 
FIG 11.1  H&E X40 Hodgkins 
lymphoma showing binucleate 
RS cells 
FIG11.3   Hodgkins 
lymphoma  IHCx40 CD45 
strong membrane positive 
FIG 11.4  Hodgkins Lymphoma 
IHC X10 Tumour cells show 
Ki67 Negative 
FIG  11.2   H&E X100  
Hodgkins lymphoma showing  
mononuclear RS cells 
HODGKINS   LYMPHOMA  - SPLEEN 
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DISCUSSION 
Malignant lymphomas are the third most common cancer in the 
childhood. The distinction between non Hodgkins lymphoma of adults 
and  those of children is important because children usually present with 
diffuse extranodal disease when compared with adults, in whom the 
primary nodal disease is more common.
[66]
Primary GI malignancies is the 
commonest extranodal site of involvement in children. Nevertheless, 
primary GI lymphomas are rare in children and represent less than 5% of 
all paediatric population with very limited data available in Indian 
population.
[67]
 
Many biological markers have been examined as potential tools for 
the evaluation of the biological behavior of gastrointestinal lymphoma in 
order to predict its clinical outcome. Among these, immunohistochemical 
staining of proliferation marker Ki-67 have been proposed to be of 
prognostic value. In the present study, immunohistochemical evaluation 
was done in 30 cases of gastrointestinal Lymphoma and an attempt was 
made to correlate the Ki-67 labeling index with the known prognostic 
factors of GI Lymphoma 
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          Among 2834 paediatric patients with GI pathology, in the Institute 
of Child Health, Egmore, 30 patients (0.48%) were reported to have GI 
lymphoma during the period of study from 2007 to 2011. Of these 2834 
GI specimens received for histopathological examination, 1.34% of the 
cases were reported to be malignant.  
The peak age incidence of GI lymphoma has been reported in 5 to 
15 years age group in the literature.
[66, 67]
In the present study, mean age of 
pediatric GI lymphoma was 6.10 years (Standard deviation ± 2.482).  In 
the study done by Ahmed Morsi et al,
 [69]
 the incidence of GI Lymphoma 
in male and female was 75.7% and 24.3% respectively.  In concurrence 
with the above study, a significant male predominance (76%) of GI 
Lymphoma was noted with female patients being accounted for 24% of 
cases. 
The most common site of pediatric GI Lymphoma in present study 
is the small bowel (85%), followed by ileo-caecal region (20%), large 
intestine (6.7%) and spleen (6.7%) (Table 4). This is almost similar to the 
most of the reported series in the literature.
 [69, 70, 71, 72]
 
Abdominal pain was the most common presentation (76.7%) in the 
present study(Table 4) followed by abdominal swelling (70%), vomiting 
(40%), intestinal obstruction (20%) and constipation (16.7%). In contrast 
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to most of other studies, none of our patients presented with generalized 
lymphadenopathy. Bone marrow aspiration was done in all cases, which 
revealed bone marrow infiltration in 5 cases (16.7%). The incidence of 
bone marrow infiltration was slightly higher in the present study when 
compared to other studies which range from 3.5 to 9.1%.
 [71, 74]
 
All the patients in the study group underwent complete surgical 
removal of the diseased segment of bowel or organ. The ideal treatment 
approach in GI Lymphoma remains controversial. Radical tumor 
resection followed by chemotherapy in early disease, and limited or no 
resection followed by polychemotherapy in advanced disease may be the 
justified approach. However recent studies done by Raina V et al 2006, 
have proposed the use of chemotherapy alone as an effective treatment 
option in primary GI lymphoma in all stages.
 [68]
 
 The examination of resected specimen in the study group revealed 
Burkitt lymphoma (33%), MALToma, DLBCL, Anaplastic lymphoma, 
Lymphoblastic lymphoma and Hodgkins (TABLE 7). The incidence of 
various pathological subtypes in our study was comparable to the study 
by Ahmed Morsi et al.  
Ranjan bandyopadhyay et al in his study of 6 cases showed that 
there was 50% distal small bowel involvement, except one case all were 
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males and presented with intestinal obstruction in half of cases. All cases 
had intestinal growth with 50% shows regional involvement. This is 
consistent with the current study with male predominance, small bowel 
involvement with regional lymph node. 
TABLE - 27 
 COMPARISON OF CLINICOPATHOLOGICAL FACTORS 
WITH VARIOUS STUDY GROUP. 
Study group AGE SITE Histo type 
Ranjan 
Bandyopadhyay  
et al 2011 
1 – 8 yrs (6 
cases) 
Small bowel 
(50%) 
Burkitt  (66%) 
Morsi et al 2005 1-15 yrs (43 
cases) 
Small bowel 
(35%) 
Burkitt (56%) 
Khurshed et al 
2007 
1-19 yrs (60 
cases) 
Colon (85%) Burkitt  (47%) 
Bethel CA et al 
1997 
1-17 yrs (55 
cases) 
Small 
intestine 
(22%) 
Burkitt (38%) 
Current study 1-12 yrs (30 
cases) 
Small 
intestine 
(66%) 
Burkitt (33%) 
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 With cut-off value of 60%, we found that Ki-67 has statistically 
significant impact on overall survival in patients with pediatric GI 
lymphoma. However, high Ki-67 value, which was associated with 
poorer overall survival in the study, has not shown any significance in 
predicting disease free survival.  
 Cell proliferation rate is a vital parameter in grading neoplasm and 
predicting clinical outcome. In our study, Burkitt lymphoma showed 
highest Ki-67 positivity ranging between 80 – 98%, followed by 
lymphoblastic lymphoma (92%), anaplastic lymphoma (80%), DLBCL 
(40-80%) and MALToma (10-50%). The present study clearly 
demonstrates that Ki-67 may add both diagnostic and prognostic value in 
pediatric GI lymphoma.  
 Among the 3 patients with recurrence of disease after treatment, 
only one is alive and is now on second line chemotherapy. There were  
5 deaths in our study with 2 death due to disease recurrence, 2 due to 
chemotherapy complication and 1 due to sepsis. 
 Ann Arbor classification or its modification by Musshoff  was 
applied by most author to describe the extent of disease. In our study we 
applied St. Jude staging system to describe the extent of disease. Most of 
our patients belonged to stage IIE disease with disease free survival of 
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88% when compared to advanced (stage IV E) disease with disease free 
survival of 37.5%. In a similar study by Patte C et al, 2001, showed that 
patients with Stage IIE has disease free survival of about 98 to 100% 
versus 76% in those with most extensive disease.
 [70,71]
 Most other 
publications have stated an survival rate ranging from 24 to 87% for 
intestinal lymphoma, which was 83.3% in our series and 80.6 % in other 
prospective study by Ahmed et al. In view of diverging definitions, 
various staging classification, small cohort of patients and different 
histological definition in most publication, it is difficult to have a more 
detailed analysis concerning stage and histological subtypes. 
 The survival analysis in the present study has shown that bone 
marrow infiltration, extensive disease, Burkitt’s type, advanced stage of 
disease, non responders to chemotherapy and high Ki-67 values were 
significantly associated with poorer overall survival as shown in (TABLE 
22). This fact matches with other studies showing that the outcome 
depends more on the tumor burden at diagnosis
[75]
 and can be predicted 
by high Ki-67 value, Serum LDH, interleukin-2, B-2 microglobulin 
levels.
[71,72] 
 Bone marrow infiltration, extensive disease, Burkitt’s type, 
advanced stage of disease and non responders to chemotherapy were in 
addition found to significantly influence the disease free survival. This is 
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consistent with earlier reports
[71,72,73,74]
  demonstrating that disease free 
survival is influenced by the extent of disease at the initiation of therapy.  
 Raina V et al in the study sample of 77 new cases of primary 
gastrointestinal lymphoma over the period of 15 years have found that 
gastrointestinal tract is the most common extranodal site and the 
treatment modality in his studies demonstrates that chemotherapy alone 
has emerged as an effective option despite surgical resection and 
conclude organ preservation strategy using chemotherapy alone which 
can be successfully employed in a significant number of patients with 
primary Non Hodgkins Lymphoma. 
 Assigning patients to appropriate therapy depending upon their risk 
stratification has become the rule with different protocols. A patient with 
localised disease requires less intensive therapy than those with extensive 
disease. It is therefore necessary that patient should not be over treated. 
Pediatric GI lymphoma patients in whom complete resection has been 
done require only few course of chemotherapy without compromising 
final outcome. On the contrary, patients with high risk groups (those with 
advanced or extensive disease) required intensive therapy with multiple 
drugs to achieve similar outcome in the present study. 
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         To conclude, we noticed a higher prevalence of Burkitt’s among 
primary paediatric GI Lymphomas and  prognosis can be interpreted by 
using Ki-67 proliferative index. Hence, Ki-67 labeling index could be 
helpful for clinicians to recognise patients with  high risk for recurrence 
and poor survival in combination with other prognostic factors like bone 
marrow infiltration, histological type, stage and response to 
chemotherapy.
 
 
  
 
 
 
 
 
 
 
 
 
SUMMARY
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SUMMARY 
 The percentage of Gastrointestinal Lymphoma among the 6,300 
surgical samples received at Egmore Institute of  Child Health in 
the year 2007 to 2011 is 0.48%.  
 The distribution of non- neoplastic GI lesions were 98.4%, benign 
were  0.42% and malignant tumours were 1.34%.  
 Paediatric GI Lymphoma had a peak incidence in the age group of 
3-11years. 
 70% cases of gastrointestinal lymphoma were reported in males 
and 30% in females.  
 The  most  common  location  of  gastric  cancer  was  at  the Ileum 
which constituted about 66.7% of the cases.  
 The most common histological type was Burkitt which accounted 
for 33.3% of  cases.  
 Most of the tumours (73.3%) presented in stage IIE.  
 The mean Ki-67 LI was 58.5%  
 High Ki-67 Li was seen in 56.7% of cases and low LI in 43.3% of 
cases. 
 There  was  increasing  percentage  of  cases  with  high  Ki-67  LI  
with Extensive involvement, Stage IVE, BM infiltration. 
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 No significant association between Overall Survival rates with age, 
gender, tumour site. 
 There is significant association between Ki-67 with Overall 
Survival rate. 
 
 
 
 
 
 
 
CONCLUSION
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CONCLUSION 
 The incidence of paediatric GI lymphoma was lower (0.48%) in the 
present study when compared to western population (1.2%). 
 The mean age of presentation was 6.1 year with male 
predominance. 
 Different types of lymphoma are associated with significantly 
different Ki-67 values. In this study, a 60% Ki 67 cut-off value 
appear to have a predict value for overall survival and can help thus 
clinicians to distinguish between GI  lymphoma with good and 
poor outcome. 
 Stage is the most significant prognostic factor and localised disease 
is associated with better survival.  
 In conclusion the role of Ki-67 in growth and aggressiveness of GI 
lymphoma is complex and poorly understood. 
 However, Ki-67 labelling index could be helpful for clinicians to 
recognise patients with high risk for recurrence and poor survival 
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in combination with other prognostic factors like bone marrow 
infiltration, histological type, stage and response to chemotherapy. 
 However, a large sample size and follow-up of this subset of 
patients for 10 or more years could help to identify the role of Ki-
67 and other factors as long-term prognostic indicators in patients 
with GI lymphoma.
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ANNEXURES 
 
 
 
 
 
 
 
ANNEXURE – I  
PROFORMA  
Case number             :                   Name  :  
HPE number             :          Age     :  
IP number                 :              Sex      :  
Clinical history         :  
Risk factors, if any   :  
Clinical diagnosis     :  
Imaging                    :  
Previous HPE report: 
Nature of specimen  :  Complete resection /Partial resection / 
  Others     
  GROSS   
Tumour site                    :  
Tumour size                   :  
Tumour configuration    :                            Depth of invasion:  
Margins                          :      Proximal   :                      Distal : 
 
 
Depth of invasion         :  
Margins                        :      Proximal :  Free  /  Involved  
      Distal       :  Free  /  Involved  
Associated findings:  
Total number of nodes dissected:                     Number of nodes involved:  
Distant metastasis         :  
St. Jude staging                :  
IMMUNOHISTOCHEMISTRY  
  CD3, CD20, CD45  :  Intensity  
     % of tumour cells showing reaction. 
  Ki-67 score:    Intensity –   
           % of tumour nuclei showing reaction -   
 
 
ANNEXURE - II 
The Staging System Adopted was The St. Jude Staging System For 
Childhood Non-Hodgkin’s Lymphoma   
STAGE I - A single (extranodal) or single anatomic area 
                    (Nodal), excluding mediastinum or abdomen 
STAGE II- A single tumour (extranodal) with regional node 
                     involvement on same side of diaphragm: 
                     Two or more nodal areas 
                     Two single (extranodal) tumours with or without 
                         regional node involvement 
                    A primary gastrointestinal tract tumour with or 
                         without associated mesenteric node involvement, 
                         grossly, completely resected 
STAGE III -Tumour on both sides of the diaphragm: 
                        a- Two single tumours (extranodal) 
                        b- Two or more nodal areas 
                       Or all extensive primary intraabdominal disease, 
                             unresectable 
 
 
                      Or all primary paraspinal or epidural tumours 
                            regardless of other sites 
                      Or all primary intrathoracic tumours 
                            (Mediastinal, pleural, or thymus) 
STAGE IV- Any of the above with initial central nervous 
                      System or bone marrow involvement 
 
 
 
ANNEXURE III 
IMMUNOHISTOCHEMISTRY PROCEDURE 
 1.  4µ thick sections were cut from formalin fixed paraffin embedded 
tissue samples and transferred to gelatin-chrome alum coated slides.  
2.  The slides were incubated at 58ºC for overnight.  
3.  The sections were deparaffinized in xylene for 15 minutes x 2 
changes.  
4.  The  sections  were  dehydrated  with  absolute  alcohol  for  5  
minutes  x  2 changes.  
5.  The sections were washed in tap water for 10 minutes.  
6.  The slides were then immersed in distilled water for 5 minutes.  
7.  Heat  induced  antigen  retrieval  was  done  with  microwave  oven  in          
appropriate temperature with appropriate buffer for 20 to 25 minutes.  
8.  The slides were then cooled to room temperature and washed in 
running tap water for 5 minutes.  
9.  The slides were then rinsed in distilled water for 5 minutes.  
10. Wash  with  appropriate  wash  buffer  (citrate  buffer)  for  5  minutes  
x  2 changes.  
11. Apply peroxidase block over the sections for 10 minutes.  
12. Wash the slides in citrate buffer for 5 minutes x 2 changes.   
13. Cover the sections with power block for 15 minutes.  
 
 
14. The  sections  were  drained  (without  washing)  and  appropriate  
primary antibody was applied over the sections and incubated for 2 hours 
(Ki-67) and  1hour for CD3,CD20 and CD45.  
15. The slides were washed in citrate buffer for 5 minutes x 2 changes.  
16. The slides were covered with Super Enhancer for 30 minutes.  
17. The slides were washed in citrate buffer for 5 minutes x 2 changes.  
18. The slides were covered with SS Label for 30 minutes.  
19. Wash in citrate buffer for 5 minutes x 2 changes.  
20. DAB substrate was prepared by diluting 1 drop of DAB chromogen to 
1 ml of   DAB buffer.  
21. DAB substrate solution was applied on the sections for 8 minutes.  
22. Wash with citrate buffer solution for 5 minutes x 2 changes.  
23. The slides are washed well in running tap water for 5 minutes.  
24.  The sections were counterstained with Hematoxylin stain for 2 
seconds (1 dip).  
25. The slides are washed in running tap water for 3 minutes.  
26. The slides are air dried, cleared with xylene and mounted with DPX.  
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Proc              -    Procedure  
C/P               -      Complete / Partial Resection 
Loc/Ext        -    Localised/Extensive  
Hist.             -    Histological  
Mesen LN     -    Mesenteric Lymph Node status  
BMI             -     Bone marrow infiltration  
Precon CT   -    Preconditioning chemotherapy  
Resp            -     Response  
CT               -      Chemotherapy 
YR              -       Year 
SR              -      Survival 
A/D         -       Alive/Dead                 
Recur         -      Recurrence 
NR             -      No Recurrence 
 
ABSTRACT 
 
INTRODUCTION:  
The  variable  prognosis  of  Gastrointestinal lymphoma within  a  
pathological  stage  necessitates  the identification of subgroups of patients with a 
more aggressive disease.   
AIM: 
The aim of the present study was to identify the  incidence  and  distribution  
of paediatric lymphomas, to evaluate conventional morphological prognostic 
parameters among the various histopathological subtypes by immunophenotyping  
and to evaluate the expression of  Ki67 in GI lymphoma and correlate the findings 
with several clinico-pathological features and prognosis.  
MATERIALS AND METHODS:  
 
         Formalin-fixed  paraffin-embedded  tissue  samples  from  30  paediatric 
cases  treated by  surgical resection  for gastrointestinal lymphoma in the year 2007 
to 2011 were studied by immunohistochemistry, using monoclonal antibodies to 
Ki67,CD3,CD20 and CD45. The results were correlated with clinico-pathological 
features.  
 RESULTS:  
 
        Higher Ki-67 labeling index correlated significantly with overall survival rate. 
Increasing Ki-67 labeling index was associated with Bone marrow infiltration and 
advanced stage. The mean Ki-67 labeling index was higher in aggressive 
lymphoma such as Burkitt, anaplastic lymphoma and diffuses large B cell 
lymphoma.   Ki-67 was identified as important prognostic factors. 
CONCLUSION:   
         Different types of lymphoma are associated with significantly different Ki-67 
values. In this study,   60% Ki 67 cut-off value appear to have a predict value for 
overall survival and can help thus clinicians to distinguish between GI  lymphoma 
with good and poor outcome. The role played by cell proliferation in the growth 
and aggressiveness of gastric tumours is complex and still not clarified. Identifying 
the overexpression of  Ki -67 LI in gastrointestinal lymphoma could be useful as 
independent prognostic markers in identification of patients at high risk of 
recurrence and poor survival. Follow up of these patients for 10 more years could 
throw more light on the role of   Ki-67 LI as long term prognostic indicators.  
KEYWORDS:  Gastrointestinal lymphoma-B Cell Type- Ki-67. 
